PR PolyResearch
Join Free
NASDAQ

Axsome Therapeutics, Inc. (AXSM)

♄ 593 Thanks from members

Axsome Therapeutics (AXSM) presents a stark dichotomy: robust 46% year-on-year product revenue growth driven by Auvelity is counterbalanced by persistent net losses, rising SG&A costs, and a split market sentiment between optimistic Wall Street analysts and skeptical retail investors.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →

Other Nasdaq Tickers

NASDAQ
GraniteShares 2x Long AAPL Daily ETF (AAPB)
NASDAQ
Apple Inc. (AAPL)
NASDAQ
Direxion Daily AAPL Bear 1X ETF (AAPD)
NASDAQ
Ascentage Pharma Group International - American Depository Shares (AAPG)
NASDAQ
Direxion Daily AAPL Bull 2X ETF (AAPU)
NASDAQ
Rocket Pharmaceuticals, Inc. - Warrant (RCKTW)